Immune markers and kidney dialysis outcomes
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This trial looks at two blood markers, the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), in people on dialysis. It aims to see if high levels of these markers are linked to health outcomes, which could help doctors better care for dialysis patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced kidney failure (end-stage renal disease) and have been on dialysis for at least 3 months.
- You do not have an autoimmune disease (like lupus or rheumatoid arthritis).
- You do not have liver cirrhosis.
- You do not have a weakened immune system.
- You do not have cancer (currently or in the past that is active).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at two blood tests (D-dimer and CRP) to see if they can help predict heart risks in people on long-term dialysis. It may help doctors better understand your heart health and prevent future problems.
This study looks at two simple blood tests (neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio) to see if they can help predict how chronic kidney disease (CKD) will progress over time. It aims to find new ways to monitor your kidney health.
This study looks at how the body’s defense systems (immune system and related signals) behave in people with chronic kidney disease. It may help doctors understand what is driving inflammation and related complications in dialysis patients.
This study looks at whether certain blood test ratios (albumin/globulin and platelet/albumin) can help identify or predict lupus nephritis, a kidney problem caused by lupus. It may help doctors better understand and manage kidney involvement in lupus patients.
This study looks at two simple blood tests to see if they can help doctors understand and predict how lupus-related kidney disease (lupus nephritis) is progressing. The goal is to improve monitoring and treatment decisions for people with this condition.
This study measures how well a dialysis method called haemodiafiltration removes waste products from the blood, tracks how patients feel, and monitors sodium balance. It aims to improve treatment for people with kidney failure on dialysis.
Hear when a new Hemodialysis Patient trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.